2017
Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis
Atzmony L, Mimouni I, Reiter O, Leshem Y, Taha O, Gdalevich M, Hodak E, Mimouni D. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. Journal Of The American Academy Of Dermatology 2017, 77: 691-699. PMID: 28645646, DOI: 10.1016/j.jaad.2017.05.006.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCohort StudiesCross-Sectional StudiesHematologic NeoplasmsHumansNeoplasmsPemphigoid, BullousConceptsPooled analysis of case-control studiesAnalysis of cross-sectional studiesStudy designAnalysis of case-control studiesMeta-analysisEstimate pooled odds ratiosBullous pemphigoidCross-sectional studyPooled odds ratioCase-control studyAssociation of BPOverall cancerRandom-effects modelAssociation of bullous pemphigoidWell-designed studiesCase-controlOdds ratioCohort studySystematic reviewOverall malignancyAssociated with malignancyCochrane LibraryLarynx cancerPooled analysisEffects modelRisk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal Of The American Academy Of Dermatology 2017, 77: 88-97.e5. PMID: 28495497, DOI: 10.1016/j.jaad.2017.01.037.Peer-Reviewed Original ResearchConceptsChronic HBV infectionBiologic therapyHBV infectionViral reactivationAntiviral prophylaxisCore antibodyHCV infectionHepatitis BSafety of biologic therapiesHistory of viral hepatitisSystematic reviewIsolated core antibodyHBV core antibodyLow-risk patientsRetrospective cohort study designRetrospective cohort studyReactivated HBV infectionCohort study designPsoriasis patientsViral hepatitisEvaluate safetyFollow-upCohort studyPrimary outcomeTreatment duration
2010
Incidence of Cytomegalovirus-associated thrombosis and its risk factors: A case-control study
Atzmony L, Halutz O, Avidor B, Finn T, Zimmerman O, Steinvil A, Zeltser D, Giladi M, Justo D. Incidence of Cytomegalovirus-associated thrombosis and its risk factors: A case-control study. Thrombosis Research 2010, 126: e439-e443. PMID: 20926120, DOI: 10.1016/j.thromres.2010.09.006.Peer-Reviewed Original ResearchConceptsAcute CMV infectionAssociated with thrombosisCMV infectionConsecutive patientsRisk factorsControl groupSex-matched consecutive patientsStudy groupCohort of patientsTertiary medical centerConsecutive matched patientsBinary logistic regression analysisLogistic regression analysisVenous thrombosesVenous thrombosisMatched patientsThrombosis incidenceInherited predispositionMedical chartsArterial thrombosisPhysician awarenessThrombosisAge-matchedPatientsMedical Center
2009
C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia
Justo D, Lachmi S, Saar N, Joffe E, Atzmony L, Mashav N, Henis O, Sade B, Chundadze T, Steinvil A, Paran Y. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. European Journal Of Internal Medicine 2009, 20: 518-521. PMID: 19712857, DOI: 10.1016/j.ejim.2009.03.008.Peer-Reviewed Original ResearchConceptsCAP patientsChronic obstructive pulmonary disease exacerbationsCommunity acquired pneumoniaChronic obstructive pulmonary diseaseInitiation of antibacterial treatmentChronic obstructive pulmonary disease exacerbation patientsCRP levelsExacerbation patientsC-reactive protein velocityAntibacterial treatmentTreated with cephalosporinsChronic obstructive pulmonary disease patientsDays of hospitalizationChest X-rayInternal medicine departmentObstructive pulmonary diseaseProductive coughAntibiotic administrationDisease exacerbationStudy groupPulmonary diseaseCRPPatientsExacerbationMedicine department